New Findings in Tumors Described from Regina Elena National Intstitute for Cancer Treatment and Research (Cancer stem cells: perspectives for therapeutic targeting)
By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Current study results on Tumors have been published. According to news originating from Rome, Italy, by NewsRx correspondents, research stated, "Cells with 'stemness' and tumor-initiating properties have been isolated from both hematological and solid tumors. These cells denominated as cancer stem cells (CSCs), representing rare populations within tumors, have the ability to metastasize and are resistant to standard therapies and immunotherapy."
Our news journalists obtained a quote from the research from Regina Elena National Intstitute for Cancer Treatment and Research, "Heterogeneity and plasticity in the phenotype of CSCs have been described in relation to their tissue origin. Few definitive markers have been isolated for CSCs from human solid tumors, limiting their usage for in vivo identification of these cells. Nevertheless, progress in the emerging CSCs concept has been achieved gaining, at least for some type of tumors, their biological and immunological characterization. The recent identification of molecules and signaling pathways that are up-regulated or aberrantly induced in CSCs allowed the development of small agents for specifically targeting of CSCs. A general low immunogenic profile has been reported for CSCs with, in some cases, the identification of the mechanisms responsible of the impairment of cell-mediated immune responses. These concepts are discussed in the context of this review."
According to the news editors, the research concluded: "Although CSCs still need to be fully characterized, potential candidate markers and/or signaling pathways, to be exploited for the design of novel CSC-targeting therapeutic strategies, are described in this review."
For more information on this research see: Cancer stem cells: perspectives for therapeutic targeting. Cancer Immunology Immunotherapy, 2015;64(1):91-97. Cancer Immunology Immunotherapy can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA (see also Tumors).
The news correspondents report that additional information may be obtained from C. Maccalli, Regina Elena Inst Canc Res, Rome, Italy.
Keywords for this news article include: Rome, Italy, Europe, Cancer, Tumors, Oncology, Therapeutics, Stem Cell Research
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC